General Information |
| Summary |
This is an open-label, Phase I study of QN-023a (allogeneic CAR-NK cells targeting CD33) in relapsed/refractory Acute Myeloid Leukemia (AML).
The clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-023a in patients with relapsed/refractory AML,where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled. |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2022-10-28 |
| End date (estimated) |
2025-10-21 |
| Clinical feature |
| Label |
acute myeloid leukemia |
| Link |
http://purl.obolibrary.org/obo/DOID_9119 |
| Description |
A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.; OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT05601466 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05601466 |
| Other study identifiers |
|
| Source weblink |
https:/clinicaltrials.gov/ct2/show/NCT05601466 |
| Sponsors |
Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin, China
|
| Collaborators |
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
18 |
